|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function显示文摘在肿瘤和免疫系统之间的相互作用仍然糟糕被理解。重要临床的回答在对 CTLA4 和 PD-1/PD-L1 检查点与抗体对待的癌症病人被完成了;然而,仅仅病人的小部分对治疗作出回应,显示需要探索为癌症治疗的另外的 co 禁止的分子。B7-H3, B7 总科的一个成员,被我们以前显示出禁止 T 房间激活和 autoimmunity。在这研究,我们在肿瘤免疫分析了 B7-H3 的功能。B7-H3 的表示在多重肿瘤线,渗入肿瘤的树枝状的房间,和巨噬细胞被发现。与对抗抗体对待到 B7-H3 的 B7-H3-deficient 老鼠或老鼠显示出多重肿瘤的减少的生长,它取决于 NK 和 CD8 + T 房间。与细胞毒素的淋巴细胞表示的通常认为的受体, B7-H3 禁止了他们的激活,并且它的缺乏在忍受肿瘤的鼠标导致了增加的细胞毒素的淋巴细胞功能。B7-H3 和 PD-1 的联合封锁导致了迟了阶段的肿瘤的进一步提高的治疗学的控制。一起拿,我们的结果显示 B7-H3 检查点可以对癌症为免疫疗法用作一个新奇目标。 | Young-hee Lee Natalia Martin-Orozco Peilin Zheng Jing Li Peng Zhang Haidong Tan Hyun Jung Park Mira Jeong Seon Hee Chang Byung-Seok Kim Wei Xiong Wenjuan Zang Li Guo Yang Liu Zhong-jun Dong Willem W Overwijk Patrick Hwu Qing Yi Larry Kwak Zhiying Yang Tak W Mak Wei-Li Laszlo G Radvanyi Ling Ni Dongfang Liu Chen Dong | 2017 | Cell Research2017，27，8： | 29 |
| 2 | Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development显示文摘 | Geok Choo Sim Jessica Chacon Cara Haymaker Krit Ritthipichai Manish Singh Patrick Hwu Laszlo Radvanyi | 2014 | BioDrugs2014，，： | 1 |
| 3 | Harnessing the Power of the Immune System to Target Cancer显示文摘 | Gregory Lizée Willem W. Overwijk Laszlo Radvanyi Jianjun Gao Padmanee Sharma Patrick Hwu | 2013 | Annual Review of Medicine2013，，： | 1 |
| 4 | Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy显示文摘 | Chantale Bernatchez Laszlo G. Radvanyi Patrick Hwu | 2012 | Seminars in Oncology2012，，2： | 1 |
| 5 | Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients显示文摘Background:Compared to the general population,cancer patients are at higher risk of morbidity and mortality following SARS-CoV-2 infection.The immune response to a two-dose regimen ofmRNA vaccines in cancer patients is generally lower than in immunocompetent individuals.Booster doses may meaningfully augment immune response in this population.We conducted an observational study with the primary objective of determining the immunogenicity of vaccine dose three(100μg)of mRNA-1273 among cancer patients and a secondary objective of evaluating safety at 14 and 28 days.Methods:The mRNA-1273 vaccine was administered~7 to 9 months after administering two vaccine doses(i.e.,the primary series).Immune responses(enzyme-linked immunosorbent assay[ELISA])were assessed 28 days post-dose three.Adverse events were collected at days 14(±5)and 28(+5)post-dose three.Fisher exact or X^(2)tests were used to compare SARS-CoV-2 antibody positivity rates,and paired t-tests were used to compare SARS-CoV-2 antibody geometric mean titers(GMTs)across different time intervals.Results:Among 284 adults diagnosed with solid tumors or hematologic malignancies,dose three of mRNA-1273 increased the percentage of patients seropositive for SARS-CoV-2 antibody from 81.7%pre-dose three to 94.4%28 days post-dose three.GMTs increased 19.0-fold(15.8-22.8).Patients with lymphoid cancers or solid tumors had the lowest and highest antibody titers post-dose three,respectively.Antibody responses after dose three were reduced among those who received anti-CD20 antibody treatment,had lower total lymphocyte counts and received anticancer therapy within 3 months.Among patients seronegative for SARS-CoV-2 antibody pre-dose three,69.2%seroconverted after dose three.A majority(70.4%)experienced mostly mild,transient adverse reactions within 14 days of dose three,whereas severe treatment-emergent events within 28 days were very rare(<2%).Conclusion:Dose three of the mRNA-1273 vaccine was well-tolerated and augmented SARS-CoV-2 seropositivity in cancer patients,especially those who did not seroconvert post-dose two or whose GMTs significantly waned post-dose two.Lymphoid cancer patients experienced lower humoral responses to dose three of the mRNA-1273 vaccine,suggesting that timely access to boosters is important for this population. | Anna Giuliano Barbara Kuter Shari Pilon-Thomas Junmin Whiting Qianxing Mo Brett Leav Bradley Sirak Christopher Cubitt Christopher Dukes Kimberly Isaacs-Soriano Kayoko Kennedy Somedeb Ball Ning Dong Akriti Jain Patrick Hwu Jeffrey Lancet | 2023 | Cancer Communications2023，43，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员